Advertisement
UK markets close in 8 hours 2 minutes
  • FTSE 100

    8,275.31
    +2.85 (+0.03%)
     
  • FTSE 250

    20,514.47
    +15.75 (+0.08%)
     
  • AIM

    774.60
    +2.22 (+0.29%)
     
  • GBP/EUR

    1.1825
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2653
    -0.0007 (-0.06%)
     
  • Bitcoin GBP

    51,118.78
    -924.98 (-1.78%)
     
  • CMC Crypto 200

    1,354.21
    -6.11 (-0.45%)
     
  • S&P 500

    5,473.17
    -13.86 (-0.25%)
     
  • DOW

    39,134.76
    +299.90 (+0.77%)
     
  • CRUDE OIL

    82.34
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,370.40
    +1.40 (+0.06%)
     
  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     
  • HANG SENG

    18,046.93
    -288.39 (-1.57%)
     
  • DAX

    18,234.01
    -20.17 (-0.11%)
     
  • CAC 40

    7,667.03
    -4.31 (-0.06%)
     

One Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their stake by 106% in the previous year

Looking at Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for Atea Pharmaceuticals

Atea Pharmaceuticals Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Director Polly Murphy bought US$103k worth of shares at a price of US$8.57 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$5.49). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was Polly Murphy.

ADVERTISEMENT

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Atea Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Atea Pharmaceuticals insiders own about US$40m worth of shares. That equates to 9.1% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Atea Pharmaceuticals Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Atea Pharmaceuticals and their transactions don't cause us concern. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Atea Pharmaceuticals.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here